Day & Ennis’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $3.02M | Buy |
19,501
+24
| +0.1% | +$3.5K | 1.07% | 22 |
|
|
2023
Q3 | $2.9M | Sell |
19,477
-183
| -0.9% | -$26.9K | 1.08% | 24 |
|
|
2023
Q2 | $2.65M | Buy |
19,660
+381
| +2% | +$55.9K | 1.01% | 24 |
|
|
2023
Q1 | $3.07M | Buy |
19,279
+270
| +1% | +$41.3K | 1.14% | 23 |
|
|
2022
Q4 | $3.07M | Sell |
19,009
-130
| -0.7% | -$19.9K | 1.19% | 22 |
|
|
2022
Q3 | $2.57M | Buy |
19,139
+83
| +0.4% | +$11.9K | 1.07% | 30 |
|
|
2022
Q2 | $2.92M | Buy |
19,056
+614
| +3% | +$93.8K | 1.11% | 30 |
|
|
2022
Q1 | $2.99M | Buy |
18,442
+21
| +0.1% | +$3.05K | 0.99% | 33 |
|
|
2021
Q4 | $2.49M | Buy |
18,421
+280
| +2% | +$33.1K | 0.82% | 37 |
|
|
2021
Q3 | $1.96M | Buy |
18,141
+442
| +2% | +$50.5K | 0.68% | 45 |
|
|
2021
Q2 | $1.99M | Buy |
17,699
+1,298
| +8% | +$146K | 0.69% | 43 |
|
|
2021
Q1 | $1.77M | Buy |
16,401
+271
| +2% | +$29K | 0.67% | 42 |
|
|
2020
Q4 | $1.73M | Buy |
16,130
+955
| +6% | +$91.8K | 0.69% | 44 |
|
|
2020
Q3 | $1.33M | Buy |
15,175
+1,032
| +7% | +$97.2K | 0.58% | 46 |
|
|
2020
Q2 | $1.39M | Buy |
14,143
+373
| +3% | +$32.8K | 0.69% | 46 |
|
|
2020
Q1 | $1.05M | Buy |
13,770
+140
| +1% | +$11.9K | 0.6% | 43 |
|
|
2019
Q4 | $1.21M | Buy |
13,630
+1,048
| +8% | +$87K | 0.59% | 38 |
|
|
2019
Q3 | $953K | Buy |
12,582
+2,450
| +24% | +$168K | 0.49% | 41 |
|
|
2019
Q2 | $737K | Buy |
10,132
+2,671
| +36% | +$210K | 0.39% | 50 |
|
|
2019
Q1 | $601K | Sell |
7,461
-232
| -3% | -$19K | 0.34% | 50 |
|
|
2018
Q4 | $709K | Sell |
7,693
-61
| -0.8% | -$5.36K | 0.47% | 48 |
|
|
2018
Q3 | $733K | Buy |
7,754
+61
| +0.8% | +$5.79K | 0.49% | 46 |
|
|
2018
Q2 | $713K | Buy |
7,693
+84
| +1% | +$8.2K | 0.53% | 45 |
|
|
2018
Q1 | $720K | Buy |
7,609
+75
| +1% | +$8.24K | 0.59% | 42 |
|
|
2017
Q4 | $729K | Buy |
7,534
+200
| +3% | +$18.8K | 0.6% | 40 |
|
|
2017
Q3 | $652K | Sell |
7,334
-3,114
| -30% | -$237K | 0.58% | 40 |
|
|
2017
Q2 | $758K | Buy |
10,448
+226
| +2% | +$15.2K | 0.65% | 40 |
|
|
2017
Q1 | $666K | Sell |
10,222
-1,366
| -12% | -$85.9K | 0.63% | 33 |
|
|
2016
Q4 | $726K | Buy |
11,588
+430
| +4% | +$26.2K | 0.74% | 28 |
|
|
2016
Q3 | $704K | Buy |
11,158
+209
| +2% | +$13.5K | 0.74% | 27 |
|
|
2016
Q2 | $678K | Hold |
10,949
| – | – | 0.74% | 28 |
|
|
2016
Q1 | $625K | Buy |
10,949
+575
| +6% | +$32K | 0.69% | 28 |
|
|
2015
Q4 | $615K | Buy |
+10,374
| New | +$598K | 0.69% | 27 |
|
Other funds holding ABBV
Day & Ennis's ABBV Position: Q4 2023 in Review
Day & Ennis increased its AbbVie (ABBV) stake by 0.12% in Q4 2023, buying an estimated $3.5K and bringing the position to 19,501 shares worth $3.02M. The position accounts for 1.07% of the portfolio, ranked #22.
Day & Ennis first reported a position in ABBV in Q4 2015 and has held it in 33 quarters since. The position peaked at $3.07M in Q1 2023. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.
- Day & Ennis held 19,501 shares of AbbVie worth $3.02M as of Q4 2023.
- Day & Ennis bought 24 AbbVie shares in Q4 2023, an estimated $3.5K.
- AbbVie made up 1.07% of Day & Ennis's portfolio in Q4 2023, its #22 holding.
- Day & Ennis first reported a position in AbbVie in Q4 2015 and has held it in 33 quarters since.
- Day & Ennis's AbbVie position peaked at $3.07M in Q1 2023.
- 3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.
Based on Day & Ennis's 13F filing for Q4 2023, filed 18 Jan 2024.